| Amit Prasad, MD | |
|
1900 Mistletoe Blvd, Suite 100, Fort Worth, TX 76104-4014 | |
| (817) 338-1300 | |
| (628) 747-5141 |
| Full Name | Amit Prasad |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 18 Years |
| Location | 1900 Mistletoe Blvd, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104036185 | NPI | - | NPPES |
| 325283501 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | P7333 (Texas) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | P7333 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Texas Health Huguley Hospital Fort Worth South | Burleson, TX | Hospital |
| Texas Health Harris Methodist Hospital Fort Worth | Fort worth, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiac Cath Lab Of Fort Worth Lp | 2062656689 | 5 |
| Fort Worth Heart, P.a. | 4082696562 | 17 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
| Entity Name | Baylor All Saints Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083633143 PECOS PAC ID: 9830007418 Enrollment ID: O20040517000272 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
| Entity Name | Fort Worth Heart, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801939244 PECOS PAC ID: 4082696562 Enrollment ID: O20040607001334 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
| Entity Name | Cardiac Cath Lab Of Fort Worth Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649510991 PECOS PAC ID: 2062656689 Enrollment ID: O20130923000324 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
| Entity Name | Graham Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972950467 PECOS PAC ID: 8123246469 Enrollment ID: O20161229000390 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amit Prasad, MD 1900 Mistletoe Blvd, Suite 100, Fort Worth, TX 76104-4014 Ph: (214) 590-8058 | Amit Prasad, MD 1900 Mistletoe Blvd, Suite 100, Fort Worth, TX 76104-4014 Ph: (817) 338-1300 |
News Archive
Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 8 days ago
Charles A Carlton, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1622 8th Avenue, Suite 110, Fort Worth, TX 76104 Phone: 817-926-2561 Fax: 817-921-3708 | |
Paul J Garcia, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5701 Bryant Irvin Rd, Suite 302, Fort Worth, TX 76132 Phone: 817-294-9000 Fax: 817-294-9010 | |
Stevan A Gonzalez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 8th Ave, Suite 515, Fort Worth, TX 76104 Phone: 817-922-4675 Fax: 817-922-4645 | |
Jeremy Aaron Ross, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Magnolia Ave, Fort Worth, TX 76104 Phone: 817-759-7000 Fax: 817-759-7027 | |
Elie B Choufani, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 601 W Terrell Ave, Fort Worth, TX 76104 Phone: 817-852-8305 | |
Syed Hadi Jafri, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 W Terrell Ave Fl 2, Fort Worth, TX 76104 Phone: 817-820-4906 Fax: 817-820-4815 | |
Cheryl K Mcdonald, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1125 College Ave, Fort Worth, TX 76104 Phone: 817-810-9810 Fax: 817-810-9815 |